Study details
Enrolling now
An Open-label, Time-lagged, Dose-escalation Study to Evalaute the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa
University of Alabama at Birmingham
NCT IDNCT06326476ClinicalTrials.gov data as of Apr 2026
Phase
EARLY_PHASE1
Target enrollment
12
Study length
about 2.2 years
Ages
18+
Locations
1 site in AL
What this study is about
This trial is testing siplizumab for Hidradenitis Suppurativa. Subjects will receive subcutaneous doses of siplizumab over 8 weeks, with different dosages tested. Assessments will be done weekly and biweekly to monitor safety and efficacy.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Siplizumab
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
monoclonal antibody
Endpoints
Secondary: Improvement in Visual Analogue Scale (VAS) pain scores